PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics - United Kingdom
doi 10.1007/s40273-015-0355-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Review of Health Technology Assessments (HTA) of PCSK9 Inhibitors (PSCK9I)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

Voicethread: A Technology Tool Worth Your Time

Issues in Language Instruction
2018English

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

INNOVATIONS in pharmacy
2017English

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

PCSK9 Inhibitors - Alirocumab and Evolucumab: Key Insights on Differentiation in a Generic Market

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Paying for bmj.com

BMJ
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy